BioTech
Providers shouldn’t be afraid of buprenorphine for opioid use disorder making it into the hands of someone without a prescription
In December 2022, Congress repealed the “X-waiver” requirement, which had limited medical providers’ ability to prescribe buprenorphine-naloxone, one of the three medications approved by the
Joëlla W. Adams
January 5, 2024